For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

Weight loss tops many folks' list of New Year's resolutions, and lots of people are turning to cutting-edge weight-loss drugs ...

Retatrutide, a synthetic peptide with unique properties, has recently gained attention for its multifunctional roles and the ...

The news was just the latest in a cavalcade of headlines about copycat glucagon-like peptide 1 (GLP-1) agonists. The blockbuster drugs used for weight loss and to treat diabetes are in such high ...

This Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response ...

1 Cochrane Evidence Synthesis Unit Germany/UK—Düsseldorf Sub-Unit ... weight and optimising their health through lifestyle intervention programmes, glucagon-like peptide-1 (GLP-1) receptor agonists ...